147 related articles for article (PubMed ID: 36916944)
21. Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.
Permala J; Tarning J; Nosten F; White NJ; Karlsson MO; Bergstrand M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242661
[TBL] [Abstract][Full Text] [Related]
22. Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy.
Chotsiri P; Gutman JR; Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Asih PBS; L'lanziva A; Otieno K; Kariuki S; Ouma P; Were V; Katana A; Price RN; Desai M; Ter Kuile FO; Tarning J
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361303
[TBL] [Abstract][Full Text] [Related]
23. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan.
Hoglund RM; Adam I; Hanpithakpong W; Ashton M; Lindegardh N; Day NP; White NJ; Nosten F; Tarning J
Malar J; 2012 Nov; 11():398. PubMed ID: 23190801
[TBL] [Abstract][Full Text] [Related]
24. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
[TBL] [Abstract][Full Text] [Related]
25. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.
Jagannathan P; Kakuru A; Okiring J; Muhindo MK; Natureeba P; Nakalembe M; Opira B; Olwoch P; Nankya F; Ssewanyana I; Tetteh K; Drakeley C; Beeson J; Reiling L; Clark TD; Rodriguez-Barraquer I; Greenhouse B; Wallender E; Aweeka F; Prahl M; Charlebois ED; Feeney ME; Havlir DV; Kamya MR; Dorsey G
PLoS Med; 2018 Jul; 15(7):e1002606. PubMed ID: 30016328
[TBL] [Abstract][Full Text] [Related]
26. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
[TBL] [Abstract][Full Text] [Related]
27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
28. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.
Whalen ME; Kajubi R; Chamankhah N; Huang L; Orukan F; Wallender E; Kamya MR; Dorsey G; Jagannathan P; Rosenthal PJ; Mwebaza N; Aweeka FT
Clin Pharmacol Ther; 2019 Dec; 106(6):1310-1318. PubMed ID: 31173649
[TBL] [Abstract][Full Text] [Related]
29. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.
Savic RM; Jagannathan P; Kajubi R; Huang L; Zhang N; Were M; Kakuru A; Muhindo MK; Mwebaza N; Wallender E; Clark TD; Opira B; Kamya M; Havlir DV; Rosenthal PJ; Dorsey G; Aweeka FT
Clin Infect Dis; 2018 Sep; 67(7):1079-1088. PubMed ID: 29547881
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV.
Lartey M; Kenu E; Lassey A; Ntumy M; Ganu V; Sam M; Boamah I; Gilani FS; Yang H; Burch GM; Norman J; Peloquin CA; Kwara A
Clin Ther; 2020 Sep; 42(9):1818-1825. PubMed ID: 32811669
[TBL] [Abstract][Full Text] [Related]
31. A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
Moore BR; Benjamin JM; Tobe R; Ome-Kaius M; Yadi G; Kasian B; Kong C; Robinson LJ; Laman M; Mueller I; Rogerson S; Davis TME
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405866
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria.
Adam I; Tarning J; Lindegardh N; Mahgoub H; McGready R; Nosten F
Am J Trop Med Hyg; 2012 Jul; 87(1):35-40. PubMed ID: 22764289
[TBL] [Abstract][Full Text] [Related]
33. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
Cressey TR; Stek A; Capparelli E; Bowonwatanuwong C; Prommas S; Sirivatanapa P; Yuthavisuthi P; Neungton C; Huo Y; Smith E; Best BM; Mirochnick M;
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):245-52. PubMed ID: 22083071
[TBL] [Abstract][Full Text] [Related]
34. Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers.
Liu H; Zhou H; Cai T; Yang A; Zang M; Xing J
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784841
[TBL] [Abstract][Full Text] [Related]
35. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.
Moore BR; Benjamin JM; Salman S; Griffin S; Ginny E; Page-Sharp M; Robinson LJ; Siba P; Batty KT; Mueller I; Davis TM
Antimicrob Agents Chemother; 2014 Oct; 58(10):5784-94. PubMed ID: 25049242
[TBL] [Abstract][Full Text] [Related]
36. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital.
Bera E; McCausland K; Nonkwelo R; Mgudlwa B; Chacko S; Majeke B
AIDS; 2010 Jan; 24(2):283-9. PubMed ID: 19864931
[TBL] [Abstract][Full Text] [Related]
37. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
[TBL] [Abstract][Full Text] [Related]
38. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine.
Zongo I; Somé FA; Somda SA; Parikh S; Rouamba N; Rosenthal PJ; Tarning J; Lindegardh N; Nosten F; Ouédraogo JB
PLoS One; 2014; 9(8):e103200. PubMed ID: 25133389
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers.
Moore BR; Salman S; Benjamin J; Page-Sharp M; Yadi G; Batty KT; Siba PM; Mueller I; Davis TM
Antimicrob Agents Chemother; 2015 Jul; 59(7):4272-8. PubMed ID: 25963980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
